期刊文献+

盐酸莫西沙星的合成工艺改进 被引量:1

Process Improvement on Synthesis of Moxifloxacin hydrochloride
下载PDF
导出
摘要 目的合成盐酸莫西沙星。方法以1-环丙基-6,7-二氟-1,4-二氢-8-甲氧基-4-氧代-3-喹啉羧酸乙酯为起始原料,经硼螯合反应、与(S,S)-2,8-二氮杂双环〔4.3.0〕壬烷缩合、酸化并加水结晶制备得盐酸莫西沙星。结果合成的盐酸莫西沙星总收率约为75%。结论:本合成工艺对硼螯合反应进行了优化,不使用腐蚀和毒性的氯化锌,能够达到很好的螯合效果;螯合物与壬烷的缩合产物通过简便的后处理方式,即直接酸化继而加水析晶,制备得盐酸莫西沙星,总收率在75%左右。产品纯度高,单个杂质小于0.1%,总杂质小于0.2%,适合工业化生产。 Objective synthesize moxifloxacin hydrochloride. Method:take the 1-cyclopropyl-6, 7-difluoro-1, 4-dihydro-8-methoxy- 4-oxo- 3-ethyl quinoline carboxylate as the original materials and after the borate chelate reaction, condensation with the (S, S)-2,8-diazabicyclo[4.3.0] nonane, acidification and crystallization by adding water, we can prepare the moxifloxacin hydrochloride. The results show that the total recovery of the synthetic moxifloxacin hydrochloride is about 75%. Conclusion shows that the synthetic process takes optimization of the borate chelate reaction, and without the use of corrosive and virulent zinc chloride, a good chelation effect can be achieved, For the condensed products produced by the chelate and nonane, through simple post-processing method, can directly have the acidification reaction and then have the crystallization reaction by adding water, finally get the preparation of moxifloxacin hydrochloride, which has the total recovery of about 75%. This product has a high purity besides, the impurity of each one is less than 0.1% and the total impurity is less than 0.2%, which is suitable for industrial production.
出处 《当代化工研究》 2016年第10期121-122,共2页 Modern Chemical Research
关键词 盐酸莫西沙星 螯合 缩合 工艺优化 moxifloxacinhydrochloride chelation condensation processimprovement
  • 相关文献

参考文献5

二级参考文献54

  • 1杨世柱.几种硼配合物的合成及其光谱性质[J].华南师范大学学报(自然科学版),1994,26(2):117-123. 被引量:1
  • 2格鲁内伯格A 博施P.一种喹啉羧酸盐酸盐的新结晶型体及其制法和药物制剂[P].CN:1160052.1997-09-24. 被引量:1
  • 3乌韦·彼得森 托马斯·申克 克劳斯·葛罗赫 等.含1-二环取代-3-喹诺酮羧酸衍生物的药物组合物制备方法[P].CN:94100328.1995-01-25. 被引量:1
  • 4乌韦·彼得森 托马斯·申克 克劳斯·葛罗赫 等.7.(1-吡咯烷基)-3-喹诺酮-1,5-二氮杂萘酮羧酸衍生物和其制备方法[P].CN:89104574.1990—02—05. 被引量:1
  • 5胡必杰.实用内科学.人民卫生出版社,2001:1576. 被引量:1
  • 6[18]Stass HH, Muller F, Hundt HK, et al. Study of the influence of once-daily 400 mg moxifloxacin on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. [C]. 38(th) Intersci Conf Antimicrob Agents Chemother, Sept 24-2 7, San Diego, 1998, Abst A13 被引量:1
  • 7[19]Stass HH, Kubitza D, Schwietert H, et al. Bay12-8039 does not interact with t heophylline. [C]. 20(th) Int Cong Chemother, June 29-July 3, Sydney, 1997, Abst3 356 被引量:1
  • 8[20]Krasemann C, Meyer JM, Springsklee M. Moxifloxacin (MFX) in community-acquired pneumonia (CAP)-A bacteriologic and clinical meta-analysis. [J]. Clin Microbiol Infect, 1999,5(Suppl 3): Abst 205 被引量:1
  • 9[21]Petipretz P. Moxifloxacin(MFX) versus amoxycillin(AMOX) in the treatment of community -acqnired suspected pneumococcal pneumonia: A mutinational double -blind randonized study. [J]. Clin Microbiol Infect, 1999,5(Suppl 3):Abst 207 被引量:1
  • 10[22]Wilson R,Kubin R,Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute cxacerbations of chronic bronchitis. [J]. J Antimicrob Chemother, 1999,44(4): 501 被引量:1

共引文献59

同被引文献8

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部